MDR1 in immunity: friend or foe?

Bossennec, Marion; Di Roio, Anthony; Caux, Christophe; Ménétrier-Caux, Christine

Bossennec, Marion; Di Roio, Anthony; Caux, Christophe; Ménétrier-Caux, Christine.

Afiliación

Bossennec M; Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), Univ Lyon, Université Claude Bernard Lyon 1, Lyon France.
Di Roio A; Immunology Virology Inflammation (IVI) department, Team "Therapeutic targeting of the tumor cells and their immune stroma", Lyon, France.
Caux C; Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), Univ Lyon, Université Claude Bernard Lyon 1, Lyon France.
Ménétrier-Caux C; Immunology Virology Inflammation (IVI) department, Team "Therapeutic targeting of the tumor cells and their immune stroma", Lyon, France.

Oncoimmunology ; 7(12): e1499388, 2018.

Article en En | MEDLINE | ID: mdl-30524890

Palabras clave

MDR1; Th1.17; anti-tumor immunity; autoimmunity; chemo-resistance; combination therapy; drug efflux; immune regulation; inhibitors

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google